Lakefront Biotherapeutics (LKFT) Interest Expenses (2016 - 2026)

Lakefront Biotherapeutics (LKFT) has 11 years of Interest Expenses data on file, last reported at -$74927.7 in Q1 2026.

• On a quarterly basis, Interest Expenses rose 65.75% year-over-year to -$74927.7 in Q1 2026; TTM through Mar 2026 was $1.4 million, a 12.6% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 23.5% from the prior year.
• Interest Expenses for Q1 2026 stood at -$74927.7, down from $1.7 million in the prior quarter.
• Over the last five years, Interest Expenses for LKFT reached as high as $18.2 million in Q4 2022 and fell as low as -$4.4 million in Q1 2022.
• Historically, Interest Expenses has averaged $1.6 million across 5 years, with a median of -$74927.7 in 2026.
• Across the five-year window, Interest Expenses sank 148.87% in 2022 and jumped 85.15% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $18.2 million in 2022, then tumbled by 55.4% to $8.1 million in 2023, then tumbled by 80.2% to $1.6 million in 2024, then advanced by 2.92% to $1.7 million in 2025, then slumped by 104.53% to -$74927.7 in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were -$74927.7 in Q1 2026, $1.7 million in Q4 2025, and -$806648.0 in Q3 2025.